The Nordic AML Group (NAMLG) aims to foster excellence in research and clinical care in acute myeloid leukemia (AML) in the Nordic countries, by forming an active network of clinicians and basic and translational scientists with deep interest and experience in the field.
Photo: NASA
Find more information here.
Join us for an inspiring program filled with impactful discussions, cutting-edge insights, and the chance to connect with colleagues from across the Nordic region and beyond. The program includes TP53 Focus Sessions (Sept 17) and FLT3 Focus Sessions (Sept 18).
We will again arrange an Educational Day for clinicians (Sept 16), this time as a joint venture with the Nordic MDS Group, as well as a Special Session for Nurses (Sept 18).
The Organizing Committee is led by Conference Chair Bjørn Tore Gjertsen
and the Local Organizing Committee by Gro Gausdal.
[News? Please, let us know via namlgewg@gmail.com.]
The European Organisation for Research and Treatment of Cancer (EORTC) has developed a survey aiming to better understand how AML experts apply ELN recommendations in real-life settings, depending on available resources, as well as their therapeutic choices in first and second line, including the role of allogeneic transplantation.
The survey is estimated to take ~10 minutes and can be reached using this link: https://redcap.link/YECILeukemiaSurvey1.
At Best of ASH 2025, hematologists in Lund, Sweden present their top picks from the annual meeting of the American Society of Hematology (ASH) cutting through the volume to focus on data that change how we treat patients. Expect concise, expert-led updates on key trials, late-breaking abstracts, and their real-world implications across hematology.
Recorded 2026-01-20 on YouTube: https://www.youtube.com/live/DJrW-8hEHvI
Gösta Gahrton and Gunnar Juliusson are the editors of the Swedish-language textbook Blodets sjukdomar, which has just been released in a new, extensively revised and expanded edition. The book reflects the rapid advances in hematology – from molecular diagnostics and clonal hematopoiesis to targeted therapies and cell-based treatments.
All chapters have been thoroughly updated, and several entirely new sections have been added, covering topics such as clonal hematopoiesis, hereditary predisposition, mastocytosis, and advanced cell therapy. The book serves both as a modern introduction for physicians in training and as a practical reference for established specialists wishing to stay current with this fast-moving field.
Now available at studentlitteratur.se.
[Have an event? Please, let us know via namlgewg@gmail.com.]
Agenda and meeting link will be sent via e-mail.
Find out more »Take the chance to join an Astellas Pharma sponsored webinar with Dr. Mark J. Levis, MD, PhD, Baltimore, USA, entitled Ask the expert: FLT3 MRD testing in AML patients via […]
Find out more »
